"[T]he industry faced opportunistic manufacturers who exploited monopolies with old generic medications and captive pharmacy arrangements, and ongoing scheming by compounding pharmacies to promote sales of high-priced, no-value compound medications.” It’s pretty obvious that some shady business practices are a part of the equation."

quoted from the Drug Trend Report